BioMarin to buy rare disease drugmaker Amicus for $4.8B
Yahoo Finance·2025-12-19 11:24

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. BioMarin Pharmaceutical has agreed to buy Amicus Therapeutics in a 4.8billiondealthatwouldhandittwomarketeddrugsforrarediseasesandathirdassetinlate−stagehumantesting.Theall−cashacquisition,announcedFriday,hasBioMarinpaying4.8 billion deal that would hand it two marketed drugs for rare diseases and a third asset in late-stage human testing. The all-cash acquisition, announced Friday, has BioMarin paying 14.50 for each Amicus share, or a 33% premium to the latter’s closing stock price on Thursday. The deal has u ...